Wedbush Maintains Outperform on Tango Therapeutics, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Tango Therapeutics (NASDAQ:TNGX) and raises the price target from $11 to $13.
August 08, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on Tango Therapeutics and raises the price target from $11 to $13.
The raised price target and maintained Outperform rating from a reputable analyst at Wedbush is likely to positively impact investor sentiment and drive short-term price appreciation for Tango Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100